Indaptus Therapeutics, Inc. (INDP) stock
INDPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.17+0.02 (+0.63%)
Close on Nov 13, 2026Market cap $422.38MP/E –Yield –
Indaptus Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Indaptus Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $3.97M, down 55.8% year over year. For fiscal 2025 it was $9.34M, up 28.8% from the year before. The highest annual figure on record is $9.34M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.34M | +28.8% |
| FY2024 | Dec 31, 2024 | $7.25M | -4.9% |
| FY2023 | Dec 31, 2023 | $7.62M | +20.5% |
| FY2022 | Dec 31, 2022 | $6.32M | +150.7% |
| FY2021 | Dec 31, 2021 | $2.52M | -5.0% |
| FY2020 | Dec 31, 2020 | $2.66M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $271.20K | -82.1% |
| Q2 FY2026 | Jun 30, 2026 | $363.13K | -83.2% |
| Q1 FY2026 | Mar 31, 2026 | $491.13K | -82.5% |
| Q4 FY2025 | Dec 31, 2025 | $2.85M | +14.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.52M | +3.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.17M | +26.4% |
| Q1 FY2025 | Mar 31, 2025 | $2.81M | +76.7% |
| Q4 FY2024 | Dec 31, 2024 | $2.48M | +21.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.47M | -34.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.71M | +15.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.59M | -15.4% |
| Q4 FY2023 | Dec 31, 2023 | $2.03M | +6.4% |
| Q3 FY2023 | Sep 30, 2023 | $2.23M | +38.3% |
| Q2 FY2023 | Jun 30, 2023 | $1.48M | -1.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.88M | +44.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.91M | +102.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.61M | +130.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.51M | +285.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.30M | +164.9% |
| Q4 FY2021 | Dec 31, 2021 | $944.64K | +168.3% |
| Q3 FY2021 | Sep 30, 2021 | $697.67K | -48.3% |
| Q2 FY2021 | Jun 30, 2021 | $391.12K | -69.3% |
| Q1 FY2021 | Mar 31, 2021 | $489.72K | – |
| Q4 FY2020 | Dec 31, 2020 | $352.13K | – |
| Q3 FY2020 | Sep 30, 2020 | $1.35M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.28M | – |
See a number that looks wrong?